RxSight
RXST
228 hedge funds and large institutions have $1.98B invested in RxSight in 2024 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 75 increasing their positions, 79 reducing their positions, and 19 closing their positions.
466% more call options, than puts
Call options by funds: $4.25M | Put options by funds: $752K
174% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 19
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
26% more capital invested
Capital invested by funds: $1.58B → $1.98B (+$404M)
16% more funds holding
Funds holding: 197 → 228 (+31)
1.79% more ownership
Funds ownership: 82.74% → 84.53% (+1.8%)
5% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$18.5M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$17.3M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$16.7M |
| 5 |
BlackRock
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$33.3M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$32.1M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$10.6M |
| 4 |
Millennium Management
New York
|
-$9.5M |
| 5 |
JP Morgan Chase
New York
|
-$7.2M |
RXST Hedge Fund Activity: Q2 2024 in Review
228 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q2 2024, worth a combined $1.98B — up 26% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new RXST positions and 19 closed out — a net gain of 33 holders — while 75 added to existing stakes and 79 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27.6M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $33.3M.
- 228 institutional investors held RxSight (RXST) as of Q2 2024, up from 197 in Q1 2024.
- Funds reported $1.98B of RxSight stock for Q2 2024, up 26% quarter-over-quarter.
- 52 funds opened new RxSight positions in Q2 2024 and 19 closed out, a net change of +33 holders.
- The largest RxSight buyer in Q2 2024 was Vanguard Group, an estimated $27.6M added.
- The largest RxSight seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $33.3M sold.
Based on aggregated 13F filings for Q2 2024.